Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses an analysis of the Phase IIIb CASTING study (NCT028610) of ocrelizumab in patients with relapsing-remitting multiple sclerosis (MS) with a suboptimal response to 1-2 prior lines of therapy. Changes in Work Productivity and Activity Impairment (WPAI) scores from baseline to 2 years were used to assess the impact of treatment on work productivity. The results demonstrated that patients treated with ocrelizumab showed significant improvements in work impairment and activity impairment that were sustained over the 2-year period. Additionally, improvements in WPAI scores were found to correlate with improved MSIS-29 scores and total SymptoMScreen scores, representing the physical/psychological impact of MS and symptom burden, respectively. This interview took place during the European Academy of Neurology 2021 congress.
Giancarlo Comi has received consulting and speaking fees from Novartis, Sanofi Genzyme, Genzyme Corporation, Merck KGgA, Merck Serono SpA, Celgene Group, F. Hoffman-La Roche, Almirall SpA, & Janssen.